Marker Therapeutics, Inc. (MRKR)
1.50
+0.11
(+7.91%)
USD |
NASDAQ |
Aug 24, 16:00
1.50
0.00 (0.00%)
After-Hours: 20:00
Marker Therapeutics Enterprise Value : 11.25M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 11.25M |
| August 20, 2026 | 8.419M |
| August 19, 2026 | 9.586M |
| August 18, 2026 | 7.252M |
| August 17, 2026 | 7.418M |
| August 14, 2026 | 7.085M |
| August 13, 2026 | 6.585M |
| August 12, 2026 | 7.418M |
| August 11, 2026 | 6.752M |
| August 10, 2026 | 7.252M |
| August 07, 2026 | 6.752M |
| August 06, 2026 | 6.752M |
| August 05, 2026 | 7.085M |
| August 04, 2026 | 8.586M |
| August 03, 2026 | 8.419M |
| July 31, 2026 | 6.918M |
| July 30, 2026 | 6.752M |
| July 29, 2026 | 6.585M |
| July 28, 2026 | 7.752M |
| July 27, 2026 | 8.419M |
| July 24, 2026 | 8.419M |
| July 23, 2026 | 9.252M |
| July 22, 2026 | 8.752M |
| July 21, 2026 | 9.252M |
| July 20, 2026 | 9.419M |
| Date | Value |
|---|---|
| July 17, 2026 | 9.920M |
| July 16, 2026 | 10.42M |
| July 15, 2026 | 11.59M |
| July 14, 2026 | 12.09M |
| July 13, 2026 | 12.42M |
| July 10, 2026 | 13.25M |
| July 09, 2026 | 14.42M |
| July 08, 2026 | 14.92M |
| July 07, 2026 | 16.09M |
| July 06, 2026 | 12.75M |
| July 02, 2026 | 12.59M |
| July 01, 2026 | 12.25M |
| June 30, 2026 | 12.59M |
| June 29, 2026 | 8.704M |
| June 26, 2026 | 6.286M |
| June 25, 2026 | 6.203M |
| June 24, 2026 | 6.203M |
| June 23, 2026 | 7.203M |
| June 22, 2026 | 7.203M |
| June 18, 2026 | 6.536M |
| June 17, 2026 | 6.87M |
| June 16, 2026 | 6.87M |
| June 15, 2026 | 6.87M |
| June 12, 2026 | 7.370M |
| June 11, 2026 | 7.203M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Krystal Biotech, Inc. | 9.421B |
| Tenaya Therapeutics, Inc. | 82.22M |
| Ironwood Pharmaceuticals, Inc. | 1.027B |
| Vericel Corp. | 2.116B |
| SELLAS Life Sciences Group, Inc. | 2.984B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.826M |
| Total Expenses (Quarterly) | 1.826M |
| EPS Diluted (Quarterly) | -0.0946 |
| Earnings Yield | -32.05% |
| Normalized Earnings Yield | -32.04 |